Asset Details
Do you wish to reserve the book?
CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer
Do you wish to request the book?
CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer
2023
Overview
Purpose
Leptomeningeal metastasis (LM) is a complication of surgery for brain metastasis and is a risk factor of poor prognosis. The risk of LM is particularly high after surgery for a breast cancer metastasis to the brain. If the risk of LM after surgical resection for a brain metastasis were predictable, appropriate adjuvant therapy could be administered to individual patients to improve their prognosis. The present study aimed to reveal the genetic characteristics of brain metastases as means of predicting LM in breast cancer patients.
Methods
Ten patients with brain metastases of breast cancer presented LM after surgical resection were analyzed by whole-exome sequencing.
Results
A
chromodomain-helicase-DNA-binding protein 5 (CHD5)
gene alteration was detected in nine cases (90%), including a nonsynonymous variant in four cases and copy number deletion in five cases. CHD5 protein expression was lost in nine cases and had decreased in one case. The frequency of
CHD5
gene alteration in brain metastases with LM was significantly higher than in primary breast cancer (2.3%) or in brain metastases of breast cancer (0%) (p < 0.0001).
Conclusions
These results suggested that the
CHD5
gene alteration was associated with LM after surgical resection of breast cancer brain metastases. Searching for the gene alteration might predict the LM risk after surgical resection.
